Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Arcutis Biotherapeutics, Inc. (ARQT) is a Biotechnology company based in US with a market capitalization of $2.7B. Revenue grew 91.3% year-over-year and free cash flow was negative at -$6.3M. This page tracks ARQT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 342 employees · IPO Jan 31, 2020
Valuation
Valuation & price
$21.32as of May 17, 2026· -31.7% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
14.14
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$2.7B
Market cap
91.3%
Revenue growth (YoY)
90.2%
Gross margin
-$6.3M
Free cash flow (USD)
-$214.7M
Net debt
Net cash position
5.2%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2017 → 2025
Free cash flow by year
2017 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
9
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 6, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJun 17, 2026Filing
Insider Sell $116K · 10b5-1 PlanWelgus Howard G. · Director · $116.3K
- Insider sellJun 17, 2026Filing
Insider Sell $121K · 10b5-1 PlanLIN SUE-JEAN · Director · $120.6K
- 8-K eventJun 9, 2026Filing
Annual Meeting Results
- Insider sellMay 13, 2026Filing
Insider Sell $5KBurnett Patrick · See Remarks · $4.7K
- Insider sellMay 13, 2026Filing
Insider Sell $9KVairavan Latha · SVP Chief Financial Officer · $9.2K
- Insider sellMay 6, 2026Filing
Insider Sell $75KWatanabe Todd · Director, See Remarks · $74.9K
- Insider sellMay 6, 2026Filing
Insider Sell $32KVairavan Latha · SVP Chief Financial Officer · $31.7K
- Insider sellMay 6, 2026Filing
Insider Sell $16KBurnett Patrick · See Remarks · $16.1K
- Insider sellMay 6, 2026Filing
Insider Sell $192K · 10b5-1 PlanMatsuda Masaru · See Remarks · $192.4K
- 8-K eventMay 6, 2026Filing
Earnings Release
Questions
Frequently asked questions
What is Arcutis Biotherapeutics, Inc.'s market cap?
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalization of $2.7B.
What is ARQT's P/E ratio?
A meaningful P/E ratio is not available for ARQT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ARQT's price-to-book (P/B) ratio?
ARQT trades at 14.14 times book value per share.
Are insiders buying ARQT stock?
SEC Form 4 filings show no open-market insider buys at Arcutis Biotherapeutics, Inc. in the last 90 days (9 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.